Specialty Oncology
-
Featured
Pursuing a Gentler Path to Treat—and Potentially Cure—Acute Myeloid Leukemia
The PARADIGM study compared intensive induction chemotherapy (IC) to a novel combination therapy, azacitidine and venetoclax (aza-ven), in patients newly diagnosed with acute myeloid leukemia and eligible for IC. Results showed that aza-ven clearly outperformed IC in patients enrolled on study.
-
Improving Prostate MRI Screening for Genetically High-Risk Individuals
New research with roots at Mass General Brigham Cancer Institute shows that combining age-adjusted PSA thresholds with upfront MRI improves detection of clinically significant prostate cancer in genetically high-risk men—outperforming either test alone.
-
Experimental Drug Shows Success in Targeting Key Pathway in Recurrent Ameloblastoma
After being diagnosed with an ameloblastoma in his right mandible at age 20, a patient had numerous surgical debulking and reconstructive procedures. When further surgery was no longer possible, he enrolled in a first-in-human trial of a drug that targets the Wnt/β-catenin pathway. The drug produced a dramatic radiographic response, including near resolution of several tumor masses and reduction in pressure on the brain.
-
An Expert’s Perspective on What Daraxonrasib Means for the Future of Pancreatic Cancer Care
Phase 3 RASolute 302 data showed daraxonrasib doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer. Mass General Brigham Cancer Institute is participating in the FDA-authorized expanded access program, with approximately 50 patients consented to date.
-
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Improves Short-term Survival Regardless of Hospital Case Volume
For patients with advanced ovarian cancer, high use of neoadjuvant chemotherapy improves 90-day surgical mortality at hospitals of all case volumes, but that outcome and 5-year survival are best for patients treated at high-volume centers with high use of neoadjuvant chemotherapy.
-
Monitoring of PSA Density Advised During Active Surveillance of Prostate Cancer
Adam S. Feldman, MD, MPH, Andrew Gusev, MD, and colleagues, are the first to show that prostate-specific antigen density retains significant prognostic value after diagnosis of prostate cancer, with values ≥0.15 ng/mL2 at any point during active surveillance nearly quadrupling the risk of biopsy grade progression.
Oncology Contributors
-
Andrew T. Chan, MD, MPH
Daniel K. Podolsky Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Brigham Cancer Institute, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
Taking Aspirin Associated With Reduction in Colorectal Cancer Among High-Risk Population
-
Areej R. El-Jawahri, MD
Co-Director, Cancer Outcomes Research and Education Program, Director, Bone Marrow Transplant Survivorship Program, Mass General Brigham Cancer Institute, Professor of Medicine, Harvard Medical School
Recent Article
Digital App Improves Quality of Life for Caregivers of Patients Undergoing HSCT
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Brigham Cancer Institute, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Brigham Cancer Institute, Professor of Medicine, Harvard Medical School
Recent Article
Program Co-Chair, Keith Flaherty, MD, Recaps Key Highlights From AACR 2024
-
Keyan Salari, MD, PhD
Director of Translational Research, Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Director, Prostate Cancer Genetics Program, Mass General Brigham Cancer Institute, Assistant Professor of Surgery, Harvard Medical School
Recent Article
Improving Prostate MRI Screening for Genetically High-Risk Individuals
-
Marcela G. del Carmen, MD, MPH
President, Massachusetts General Physicians Organization, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Executive Vice President, Mass General Brigham
Recent Article
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Brigham Cancer Institute, Associate Professor of Medicine, Harvard Medical School
Recent Article
Case Series: Intraventricular Infusion of Dual-targeting CAR T-Cells for Glioblastoma
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.